Raymon Niemans
Maastricht, LI, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
Journal: Molecular cancer therapeutics
Published: May 05, 2021
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Journal: Clinical and translational radiation oncology
Published: December 07, 2018
Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: October 19, 2018
Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells.
Journal: Oncotarget
Published: April 12, 2018
New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
Journal: European journal of medicinal chemistry
Published: August 24, 2016
Synthesis and in Vivo Biological Evaluation of (68)Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography.
Journal: Journal of medicinal chemistry
Published: June 21, 2016
The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.
Journal: PloS one
Published: May 19, 2016
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.
Journal: Frontiers in oncology
Published: December 23, 2015
New ways to image and target tumour hypoxia and its molecular responses.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: July 07, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026